Baxter International (BAX) will acquire Claris Injectables for $625 million. Claris will sell Baxter its injectable generic medicines such as drugs for anesthesia and analgesics. This year Claris is expected to report revenue of $100 million. Revenue for Claris has increased by a double-digit percentage annually over the last several years as the company launched new products. The deal is expected to immediately add to Baxter's earnings. It is set to close in the second half of next year. Claris is a unit of Claris Lifesciences.
More from Video
CAG has hung onto the bulk of its recent gains, and could rise to the $50 area, according to the charts and indicators.
Breaking down an approach to the long side of this biotech stock.
AMSC CEO discusses that and China challenges.
One of pharma's biggest CEO's talks M&A action on the exchange.